VITA 34 AG announced preliminary unaudited sales results for the year of 2016. The company reported sales revenues increased in 2016 to a total of EUR 16.2 million from the EUR 14.2 million achieved in the commercial year 2015. This corresponds to a growth in turnover of approximately 14%. This development is essentially to be attributed to the increased number of newly stored stem cell deposits from umbilical cord blood and tissue as a result of the acquisitions and geographical expansion that took place in 2015.

The company reported that expected preliminary unaudited figures will be at the upper end of the forecast range or slightly above it.